Download PDF
Thromb Haemost 2006; 95(04): 618-624
DOI: 10.1160/TH05-10-0659
Blood Coagulation, Fibrinolysis and Celular Haemostasis
Schattauer GmbH

Thrombophilic risk factors and homocysteine levels in Behçet’s disease in eastern Spain and their association with thrombotic events

José M Ricart
1   Dermatology Service, La Fe University Hospital, Valencia, Spain, La Fe University Hospital, Valencia, Spain
,
Amparo Vayá
2   Hemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain
,
José Todolí
3   Internal Medicine Service, La Fe University Hospital, Valencia, Spain
,
Javier Calvo
4   Rheumatology Service, General University Hospital, Valencia, Spain
,
Piedad Villa
2   Hemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain
,
Amparo Estellés
5   Research Center, La Fe University Hospital, Valencia, Spain
,
Francisco España
5   Research Center, La Fe University Hospital, Valencia, Spain
,
Marisa Santaolaria
2   Hemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain
,
Dolores Corella
6   Department of Preventive Medicine, School of Medicine, University of Valencia, Valencia, Spain
,
Justo Aznar
2   Hemorheology and Thrombosis Unit, Department of Clinical Pathology, La Fe University Hospital, Valencia, Spain
› Author AffiliationsFinancial support: This work was supported by research grants from Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (Instituto de Salud Carlos III, FIS, PI020125) and Fundación Mutua Madrileña, Madrid, Spain.
Further Information

Publication History

Received 08 October 2005

Accepted after revision 13 February 2006

Publication Date:
30 November 2017 (online)

    Permissions and Reprints

Summary

Behçet’s disease (BD) is a chronic inflammatory disorder in which thrombosis occurs in about 30% of patients. The prothrombotic mechanisms are unknown. Thrombophilic defects and hyperhomocysteinaemia may be involved in the pathogenesis of thrombotic events, although results have been controversial. Moreover, no information is available on this issue for eastern Spain.We studied the prevalence of inherited and acquired thrombophilic risk factors in 79 patients with BD (43 men, 36 women) who had (n = 23) or did not have (n = 56) thrombosis, and in 84 healthy control subjects (42 men, 42 women). Risk factors examined were antithrombin, protein C and protein S levels, factor V Leiden, the prothrombin G20210A mutation, the methylenetetrahydrofolate reductase C677T polymorphism, and acquired thrombophilic risk factors, including anticardiolipin antibodies, lupus anticoagulant, and serum homocysteine levels. There were no differences between patients and controls in any of the parameters studied.When we studied BD patients with and without thrombotic events, the only thrombophilic defect that differed was the prothrombin G20210A mutation: Three out of 23 patients with thrombosis were carriers, compared with none of 56 patients without thrombosis (p = 0.022).Two of the three carriers developed catastrophic or recurrent thrombotic episodes; one wasa homozygous carrier of the G20210A prothrombin mutation and the other was doubly heterozygous for the G20210A prothrombin mutation and factor V Leiden. A meta-analysis demonstrated an association of factor V Leiden and prothrombin mutation with thrombosis in BD. When studies from Turkey were excluded from the meta-analysis, only the prothrombin G20210A mutation was associated with thrombosis.

Keywords

Behçet’s disease - hyperhomocysteinaemia - thrombophilic risk factors - thrombosis - meta-analysis
 

  • References

  • 1 Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet disease. Semin Arthritis Rheum 1998; 27: 197-217.
    CrossrefPubMedGoogle Scholar
  • 2 Koc Y, Güllü I, Akpek G. et al. Vascular involvement in Behçet’s disease. J Rheumatol 1992; 19: 402-10.
    PubMedGoogle Scholar
  • 3 Leiba M, Seligsohn U, Sidi Y. et al. Thrombophilic factors are not the leading cause of thrombosis in Behçet’s disease. Ann Rheum Dis 2004; 63: 1445-9.
    CrossrefPubMedGoogle Scholar
  • 4 Ates A, Düzgün N, Ulu A. et al. Factor V gene (1691A and 4070G) and prothrombin gene 20210A mutations in patients with Behçet’s disease. Pathophysiol Haemost Thromb 2003; 33: 157-63.
    CrossrefPubMedGoogle Scholar
  • 5 Navarro S, Ricart JM, Medina P. et al. Activated proteinC levels in Behçet’s disease and risk of venous thrombosis. Br J Haematol 2004; 126: 550-6.
    CrossrefPubMedGoogle Scholar
  • 6 Chafa O, Fischer AM, Meriane F. et al. Behçet syndrome associated with protein S deficiency. Thromb Haemost 1992; 67: 1-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Mammo L, Al-Dalaan A, Bahabri SS. et al. Association of factor V Leiden with Behçet's disease. J Rheumatol 1997; 24: 2196-8.
    PubMedGoogle Scholar
  • 8 Lee YJ, Kang SW, Yang JI. et al. Coagulation parameters and plasma total homocysteine levels in Behçet's disease. Thromb Res 2002; 106: 19-24.
    CrossrefPubMedGoogle Scholar
  • 9 Gurgey A, Balta G, Boyvat A. Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behçet’s disease. Blood Coagul Fibrinolysis 2003; 14: 121-4.
    CrossrefPubMedGoogle Scholar
  • 10 Kiraz S, Ertenli I, Öztürk MA. et al. Pathological haemostasis and prothrombotic state in Behçet’s disease. Thromb Res 2002; 105: 125-33.
    CrossrefPubMedGoogle Scholar
  • 11 Demiroglu H, Yalcin S, Buyukasik Y. et al. Increased erythrocyte aggregation as an indicator for an aggressive clinical course in Behçet's disease: a prospective study. Ann Rheum Dis 1998; 57: 694-6.
    CrossrefPubMedGoogle Scholar
  • 12 Nalcaci M, Pekcelen Y. Antithrombin III, protein C and protein S plasma levels in patients with Behçet’s disease. J Int Med Res 1998; 26: 206-8.
    CrossrefPubMedGoogle Scholar
  • 13 Bang D, Ji HG, Choi YS. et al. Absence of lupus anticoagulants in Behçet’s disease. Yonsei Med J 1991; 32: 326-9.
    CrossrefPubMedGoogle Scholar
  • 14 Espinosa G, Font J, Tassies D. et al. Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002; 112: 37-43.
    CrossrefPubMedGoogle Scholar
  • 15 Gul A, Ozbek U, Ozturk C. et al. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet's disease. Br J Rheumatol 1996; 35: 1178-80.
    PubMedGoogle Scholar
  • 16 Gul A, Aslantas AB, Tekinay T. et al. Procoagulant mutations and venous thrombosis in Behçet’s disease. Rheumatology (Oxford) 1999; 38: 1298-9.
    CrossrefPubMedGoogle Scholar
  • 17 Oner AF, Gurgey A, Gurler A. et al. Factor V Leiden mutation in patients with Behçet's disease. J Rheumatol 1998; 25: 496-8.
    PubMedGoogle Scholar
  • 18 Toydemir PB, Elhan AH, Tukun A. et al. Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombogenesis in Behçet’s disease. J Rheumatol 2000; 27: 2849-54.
    PubMedGoogle Scholar
  • 19 Lesprit P, Wechsler B, Piette JC. et al. Activated protein C resistance caused by factor V Arg 506®Gln mutation has no role in thrombotic manifestations of Behçet's disease. Ann Rheum Dis 1995; 54: 860.
    CrossrefPubMedGoogle Scholar
  • 20 Silingardi M, Salvarani C, Boiardi L. et al. Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet’s disease and deep vein thrombosis. Arthritis Rheum 2004; 51: 177-83.
    CrossrefPubMedGoogle Scholar
  • 21 Verity DH, Vaughan RW, Madanat W. et al. Factor V Leiden mutation is associated with ocular involvement in Behcet disease. Am J Ophthalmol 1999; 128: 352-6.
    CrossrefPubMedGoogle Scholar
  • 22 Canataroglu A, Tanriverdi K, Inal T. et al. Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behçet’s disease. Rheumatol Int 2003; 23: 236-40.
    CrossrefPubMedGoogle Scholar
  • 23 Engbersen AM, Franken DG, Boers GH. et al. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995; 56: 142-50.
    PubMedGoogle Scholar
  • 24 Altinbas A, Aytemur K, Tokgozoglu L. et al. Hyperhomocysteinaemia and activated protein C resistance in Behçet’s disease. J Intern Med 2000; 248: 267-8.
    CrossrefPubMedGoogle Scholar
  • 25 Aksu K, Turgan N, Oksel F. et al. Hyperhomocysteinaemia in Behçet’s disease. Rheumatology (Oxford) 2001; 40: 687-90.
    CrossrefPubMedGoogle Scholar
  • 26 Korkmaz C, Bozan B, Kosar M. et al. Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet’s syndrome?. Clin Exp Rheumatol 2002; 20: S30-4.
    PubMedGoogle Scholar
  • 27 Feki M, Houman H, Ghannouchi M. et al. Hyperhomocysteinaemia is associated with uveitis but not with deep venous thrombosis in Behçet’s disease. Clin Chem Lab Med 2004; 42: 1417-23.
    CrossrefPubMedGoogle Scholar
  • 28 Durand P, Prost M, Loreau N. et al. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001; 81: 645-72.
    CrossrefPubMedGoogle Scholar
  • 29 International Study Group for Behçet’s disease. Criteria for the diagnosis of Behçet’s disease. Lancet 1990; 335: 1078-80.
    PubMedGoogle Scholar
  • 30 Frezzato M, Tosetto A, Rodeghiero F. Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol 1996; 143: 1257-65.
    CrossrefPubMedGoogle Scholar
  • 31 Gandrille S, Alhenc-Gelas M, Aiach M. A rapid screening method for the factor V Arg506→Gln mutation. Blood Coagul Fibrinolysis 1995; 06: 245-8.
    CrossrefPubMedGoogle Scholar
  • 32 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
    PubMedGoogle Scholar
  • 33 Skibola CF, Smith MT, Kane E. et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 1999; 96: 12810-15.
    CrossrefPubMedGoogle Scholar
  • 34 Sutton AJ, Abrams KR, Jones DR. et al. Methods for meta-analysis in medical research. London: John Wiley; 2000
    Google Scholar
  • 35 Mader R, Ziv M, Adawi M. et al. Thrombophilic factors and their relation to thromboembolic and other clinic manifestations in Behçet’s disease. J Rheumatol 1999; 11: 2404-8.
    PubMedGoogle Scholar
  • 36 Lenk N, Ozet G, Alli N. et al. ProteinC and protein S activities in Behçet’s disease as risk factors of thrombosis. Int J Dermatol 1998; 37: 124-5.
    CrossrefPubMedGoogle Scholar
  • 37 Hull RG, Harris EN, Gharavi AE. et al. Anticardiolipin antibodies: occurrence in Behçet’s syndrome. Ann Rheum Dis 1984; 43: 746-8.
    CrossrefPubMedGoogle Scholar
  • 38 Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet´s disease. Int J Dermatol 2003; 346-51.
    PubMedGoogle Scholar
  • 39 Kosar A, Haznedaroglu IC, Buyukasik Y. et al. Activated proteinC resistance in Behçet’s disease. Rheumatol Int 1998; 17: 249-50.
    CrossrefPubMedGoogle Scholar
  • 40 Souto JC, Coll I, Llobet D. et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 80: 366-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Vayá A, Mira Y, Mateo J. et al. Prothrombin G20210A mutation and oral contraceptive use increase upper-extremity deep vein thrombotic risk. Thromb Haemost 2003; 89: 452-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Guillen M, Portoles CorellaD. et al. Prevalence of the methylenetetrahydrofolate reductase 677C®T mutation in the Mediterranean Spanish population. Association with cardiovascular risk factors. Eur J Epidemiol 2001; 170: 255-6.
    PubMedGoogle Scholar
  • 43 Mason JB, Miller JW. The effects of vitamins B12, B6, and folate on blood homocysteine levels. Ann NY Acad Sci 1992; 669: 197-203.
    CrossrefPubMedGoogle Scholar
  • 44 Hoogeveen EK, Kostense PJ, Beks PJ. et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: A population-based study. Arterioscler Thromb Vasc Biol 1998; 18: 133-8.
    CrossrefPubMedGoogle Scholar
  • 45 Glueck CJ, Shaw P, Lang JE. et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75: 132-6.
    CrossrefPubMedGoogle Scholar